viewBiocept Inc

Major US laboratory network to carry Biocept’s flagship liquid biopsy tests

Beacon Laboratory Benefit Solutions Inc, or BeaconLBS, will offer the cancer tests via its Labs-of-Choice network

cancer cell
The simple blood tests obtain the needed molecular information non-invasively and more rapidly than a tissue biopsy

Biocept Inc (NASDAQ:BIOC) announced Monday that a major laboratory-management provider now offers the company’s flagship liquid biopsy tests for patients with cancer.

The company said that Beacon Laboratory Benefit Solutions Inc, or BeaconLBS, connects physicians and their patients to its Labs-of-Choice network, which are preferred, high-quality laboratories that now including Biocept.

BeaconLBS also administers laboratory benefit management programs for health plans to improve test-ordering efficiency, test appropriateness, affordability, and quality of care for health-plan members, according to statement. 

READ: Biocept shares jump after supplier of liquid biopsy tests wins patent in China

Biocept offers the biopsy tests commercially to doctors, hospitals, clinics and researchers and are used to test and monitor for lung, breast, gastric, colorectal and prostate cancers – which represent 45% of all metastatic cancers – as well as melanoma.

The San Diego-based company says the simple blood tests obtain the needed molecular information non-invasively and more rapidly than a tissue biopsy.

"We are very pleased to become a laboratory services provider for BeaconLBS, which offers innovative laboratory management technology solutions that benefit physicians, patients and payers," said Biocept CEO Michael Nall.

"As a BeaconLBS Lab-of-Choice, more patients will have an opportunity to benefit from our liquid biopsy testing platforms, which can help physicians identify actionable biomarkers in patients diagnosed with cancer and design personalized treatment programs in order to improve outcomes." 

Biocept’s stock recently traded up 4% to $1.06 a share in New York.

Contact the author: patrick@proactiveinvestors.com

Follow him on Twitter @PatrickMGraham

Quick facts: Biocept Inc

Price: 4.2 USD

Market: NASDAQ
Market Cap: $56.25 m

Add related topics to MyProactive

Create your account: sign up and get ahead on news and events


The Company is a publisher. You understand and agree that no content published on the Site constitutes a recommendation that any particular security, portfolio of securities, transaction, or investment strategy is...

In exchange for publishing services rendered by the Company on behalf of Biocept Inc named herein, including the promotion by the Company of Biocept Inc in any Content on the Site, the Company receives from said...


Biocept announces Highmark has made a positive coverage determination on...

Biocept (Nasdaq: BIOC) CEO Michael Nall joined Steve Darling from Proactive with news the company has received positive news from Highmark, America’s fourth-largest Blue Cross Shield affiliate. That news being Biocept's Target Selector liquid biopsy assays have been accepted for medical coverage...

2 days, 13 hours ago

2 min read